Skip to main content
. Author manuscript; available in PMC: 2021 May 25.
Published in final edited form as: Nat Med. 2020 May 27;26(7):1054–1062. doi: 10.1038/s41591-020-0900-x

Extended Data Fig. 1. CONSORT diagrams for TRACERx 100 and LATTICe-A histology cohorts and patient characteristics.

Extended Data Fig. 1

a. TRACERx CONSORT diagram to illustrate sample collection and analysis of regional and diagnostic histology samples, as well as the overlap with RNA and DNA studies. b. TRACERx patient characteristics for the histology cohort. c. LATTICe-A CONSORT diagram (= 970 LUAD patients). Legends for ‘type of the analysis’ correspond to panel a. d. Demographics and clinical patient characteristics for TRACERx (top three panels) and LATTICe-A (bottom three panels) showing the distribution of age (colored by sex), distribution of smoking pack years and the proportion of patients in each pathological stage. Horizontal lines indicate the median value.